Medical Management of Persistent and Recurrent Cushing Disease

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Recent evidence supports the notion that the incidence of Cushing disease is higher than previously thought. Transphenoidal surgery, in the hands of experienced neurosurgeons, is currently considered the first-line treatment of choice. However, an examination of remission and recurrence rates in long-term follow-up studies reveals that potentially up to 40% to 50% of patients could require additional treatment. If left untreated, the resultant morbidity and mortality are high. Successful clinical management of patients with Cushing disease remains a challenge. The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease.

Original languageEnglish (US)
Pages (from-to)653-668
Number of pages16
JournalNeurosurgery Clinics of North America
Volume23
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Pituitary ACTH Hypersecretion
Therapeutics
Morbidity
Recurrence
Mortality
Incidence

Keywords

  • Adrenal steroidogenesis inhibitors
  • Cushing disease
  • Failed transphenoidal surgery
  • Glucocorticoid receptor antagonist
  • Mifepristone
  • Pasireotide
  • Recurrent Cushing disease
  • Somatostatin receptor ligands

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Medical Management of Persistent and Recurrent Cushing Disease. / Fleseriu, Maria.

In: Neurosurgery Clinics of North America, Vol. 23, No. 4, 10.2012, p. 653-668.

Research output: Contribution to journalArticle

@article{353c9f273be14044add6020d40fabe1f,
title = "Medical Management of Persistent and Recurrent Cushing Disease",
abstract = "Recent evidence supports the notion that the incidence of Cushing disease is higher than previously thought. Transphenoidal surgery, in the hands of experienced neurosurgeons, is currently considered the first-line treatment of choice. However, an examination of remission and recurrence rates in long-term follow-up studies reveals that potentially up to 40{\%} to 50{\%} of patients could require additional treatment. If left untreated, the resultant morbidity and mortality are high. Successful clinical management of patients with Cushing disease remains a challenge. The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease.",
keywords = "Adrenal steroidogenesis inhibitors, Cushing disease, Failed transphenoidal surgery, Glucocorticoid receptor antagonist, Mifepristone, Pasireotide, Recurrent Cushing disease, Somatostatin receptor ligands",
author = "Maria Fleseriu",
year = "2012",
month = "10",
doi = "10.1016/j.nec.2012.06.012",
language = "English (US)",
volume = "23",
pages = "653--668",
journal = "Neurosurgery Clinics of North America",
issn = "1042-3680",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Medical Management of Persistent and Recurrent Cushing Disease

AU - Fleseriu, Maria

PY - 2012/10

Y1 - 2012/10

N2 - Recent evidence supports the notion that the incidence of Cushing disease is higher than previously thought. Transphenoidal surgery, in the hands of experienced neurosurgeons, is currently considered the first-line treatment of choice. However, an examination of remission and recurrence rates in long-term follow-up studies reveals that potentially up to 40% to 50% of patients could require additional treatment. If left untreated, the resultant morbidity and mortality are high. Successful clinical management of patients with Cushing disease remains a challenge. The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease.

AB - Recent evidence supports the notion that the incidence of Cushing disease is higher than previously thought. Transphenoidal surgery, in the hands of experienced neurosurgeons, is currently considered the first-line treatment of choice. However, an examination of remission and recurrence rates in long-term follow-up studies reveals that potentially up to 40% to 50% of patients could require additional treatment. If left untreated, the resultant morbidity and mortality are high. Successful clinical management of patients with Cushing disease remains a challenge. The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease.

KW - Adrenal steroidogenesis inhibitors

KW - Cushing disease

KW - Failed transphenoidal surgery

KW - Glucocorticoid receptor antagonist

KW - Mifepristone

KW - Pasireotide

KW - Recurrent Cushing disease

KW - Somatostatin receptor ligands

UR - http://www.scopus.com/inward/record.url?scp=84867124316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867124316&partnerID=8YFLogxK

U2 - 10.1016/j.nec.2012.06.012

DO - 10.1016/j.nec.2012.06.012

M3 - Article

VL - 23

SP - 653

EP - 668

JO - Neurosurgery Clinics of North America

JF - Neurosurgery Clinics of North America

SN - 1042-3680

IS - 4

ER -